Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Simon Property Group Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.67 (market cap $8.04B), while Simon Property Group Inc trades at $222.94 (market cap $71.76B). The key difference: Simon Property Group Inc is far larger — about 8.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Simon Property Group Inc pays a 3.98% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SPG | |
|---|---|---|
Market Cap | $8.04B | $71.76B |
Sector | Health | Real Estate |
52-Week High | $339.75 | $227.56 |
52-Week Low | $241.71 | $159.93 |
Enterprise Value | $7.85B | $100.24B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SPG trades at $219.49, up 0.33% on the day, with a bearish technical signal despite bullish moving averages. The stock shows strong fundamentals with a 72.7% net income margin in 2025 and consistent earnings beats. Recent news highlights robust Q1 2026 results and a 4% dividend yield, though some analysts express caution on valuation. Cash flow trends indicate increased capital expenditures, with net cash flow turning negative in 2025.
Outlook remains mixed: strong leasing activity and raised FFO guidance support upside, but high debt levels and e-commerce risks weigh on sentiment. Analysts are predominantly neutral with a $214.40 consensus target, slightly below current price. Investors should balance income appeal against valuation concerns and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
